Mutations in *PUS3*, which encodes a highly conserved enzyme responsible for posttranscriptional modification of tRNA, have been shown in a single family to be a cause of nonsyndromic intellectual disability (ID).^[@R1]^ In this study, we used whole-exome sequencing (WES) to identify biallelic mutations in *PUS3* associated with syndromic ID with dysmorphic features, white matter disease (WMD), and renal abnormalities in a nonconsanguineous family from Brazil.

Clinical findings {#s1}
=================

We evaluated 2 sisters ([figure, A](#F1){ref-type="fig"}) who had ID, renal abnormalities, diffuse WMD, and dysmorphic features. Their brother was similarly affected and died at age 22 years of complications of renal disease. The parents were nonconsanguineous from Northeast Brazil and Southern Italy. We obtained approval from the institutional ethics committee and written informed consent from family members.

![Genetic and radiologic findings\
(A) Family pedigree: 2 affected individuals were compound heterozygotes for p.Arg166Gln and p.Leu366Pro *PUS3* mutations, whereas their healthy mother and sister were heterozygotes for only 1 of the mutations. (B) Sanger sequencing electropherograms showing both c.497G\>A (p.Arg166Gln) and c.1097T\>C (p.Leu366Pro) *PUS3* mutations. (C) Vertebrate protein sequencing alignment showing conserved amino acid sites for both *PUS3* mutations. (D) Scattered FLAIR hyperintensities in the cerebral white matter in P1. (E) Symmetric diffuse FLAIR hyperintensity in the cerebral white matter in P2. (F) Axial T2-weighted image discloses not only the white matter changes in P2 but also mild T2 hyperintensity in the globus pallidus bilaterally (arrows). One can notice also in P2 symmetric FLAIR hyperintensities in the cerebellar white matter (arrows in G), together with signs of brain parenchyma volume loss (E--G).](NG2018009100FF1){#F1}

The first patient (P1; III-3; [figure, A](#F1){ref-type="fig"}) was noted to have global developmental delay after age 1 year. As a child, she could understand short sentences, but expressive language was limited to monosyllables. She was diagnosed with profound ID but was independent in basic activities of daily living (ADLs). She had 2 focal dyscognitive seizures with secondary generalization, at age 18 and 23 years, responsive to carbamazepine. At age 37 years, asymptomatic proteinuria and reduced creatinine clearance were detected. At 44 years, she developed psychosis, with prominent auditory and visual hallucinations and episodes of aggression. Physical examination revealed her to be on the 10th centile for height, weight, and head circumference and to have genu valgum. In addition, neurologic examination revealed dysarthria, pseudobulbar affect, with impaired gait and balance.

The second patient (P2; III-6; [figure, A](#F1){ref-type="fig"}) also presented with short stature, neurodevelopmental delay, and dysmorphic features. She was diagnosed with acute nephritis at age 6 months and coeliac disease at age 5 years. She also developed generalized phenobarbital responsive seizures. She was able to walk and could complete ADLs with assistance. At age 20 years, she developed nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) with mesangial granular deposits and positive IgM and C3 immunofluorescence. She did not respond to steroids and developed end-stage renal failure requiring hemodialysis. Physical examination revealed that she was on the 3rd centile for height, weight, and head circumference and to have gray sclera, genu valgum, pseudobulbar affect, and dysarthria. She died at age 40 years of complications of community-acquired pneumonia.

Neuroimaging findings {#s1-1}
---------------------

MRI identified white matter abnormalities in both patients. In P1, there were scattered T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities in the cerebral white matter, more prominent in periventricular zones ([figure, D](#F1){ref-type="fig"}). In P2, there was symmetric diffuse T2/FLAIR hyperintensity in the cerebral and cerebellar white matter with extension to the subcortical areas, mild T2 hyperintensity in the globus pallidus bilaterally, and signs of brain parenchymal volume loss ([figure, E--G](#F1){ref-type="fig"}). There was no gadolinium enhancement or areas of restricted diffusion.

Genetic findings {#s1-2}
----------------

We performed WES on both patients and filtered the data for a presumed autosomal recessive inheritance pattern. There were no regions of homozygosity and no shared rare homozygous variants. However, when filtered for damaging, rare compound heterozygous mutations, we identified biallelic mutations only in *PUS3* (p.Arg166Gln;p.Leu366Pro) ([figure, B](#F1){ref-type="fig"}). Both are very rare and highly conserved residues among vertebrates. We confirmed the mutations by Sanger sequencing and demonstrated that they were inherited in trans.

Discussion {#s2}
==========

*PUS3* codes for pseudourydilate synthase, a highly conserved enzyme responsible for posttranscriptional modification of tRNA,^[@R2]^ which is critical for its structure, function, and stability. Most of these modifications have been recently recognized in a growing number of human genes leading to ID--*FTSJ1, TRMT1, NSUN2, WDR4, ADAT3,* and *PUS3*.^[@R3]^

The original report of *PUS3*-related disorder describes a family with 3 affected individuals (age: 3--15 years) from Saudi Arabia with severe ID, multifocal white matter changes, and in a single patient, epilepsy. No nephropathy was reported. WES detected a homozygous truncating mutation (p.Arg435Ter), predicting to lead to a loss of function. In our patients, affected individuals have a milder intellectual compromise and developed proteinuria/nephrotic syndrome after age 20 years. In addition, the white matter abnormalities were more extensive in our patients.

Of interest, a well-known mechanism of WMD is disruption of protein translation as is seen in mutations in mitochondrial aspartate (*DARS2*) or glutamate (*EARS2*) transfer-RNA synthase. It is also noteworthy that leukoencephalopathies usually cause progressive neurologic deterioration and not static encephalopathy with ID, as occurred in our patients.

The late-onset renal involvement observed in our patients expands the phenotype of *PUS3*-related disorder. Steroid-resistant FSGS has been rarely associated with mutations in mitochondrial tRNA in patients with other features typical of mitochondrial dysfunction.^[@R4][@R5][@R7]^ Recently, tubulopathy was reported in deficiency of tRNA N6-adenosine threonylcarbamoyltransferase, an enzyme involved in posttranscriptional tRNA modification.

This study expands the known phenotypic and allelic spectrum of *PUS3*-related disorder. In addition, it provides further evidence of the relevance of posttranscriptional modification of tRNA in neurologic diseases. Given these additional findings, we believe the phenotypic spectrum of *PUS3* mutations to be wider than the initial report.
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